N.’s treatment was complicated significantly as a consequence of myocardial injury following her SAH. Her unstable cardiac status prevented immediate treatment and her cerebral aneurysm could ...

Whether a restrictive or liberal transfusion strategy offers the best outcomes after acute brain injury has been the subject ...

A transfemoral cerebral angiogram was performed and revealed no aneurysm, cerebral sinus thrombosis, vascular malformation, or dissection to account for the SAH. The angiogram was remarkable ...

(Nasdaq: GRCE) formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being ...

GRCE READ THE FULL GRCE RESEARCH REPORT Grace Therapeutics, Inc (NASDAQ:GRCE) reported financial results and achievements for its fiscal second quarter ending September 30th, 2024 on November 13th.